fzr Inhibitors

The chemical class of fzr inhibitors encompasses a diverse array of compounds that target fzr either directly or indirectly by influencing specific signaling pathways crucial for cell cycle regulation. RO-3306, an inhibitor of cyclin-dependent kinase 1 (CDK1), indirectly impacts fzr by disrupting CDK1-mediated fzr phosphorylation events, thus affecting fzr's regulatory role in the cell cycle. Similarly, S-Trityl-L-cysteine, a microtubule polymerization inhibitor, indirectly inhibits fzr by interfering with microtubule dynamics, crucial for fzr localization and function during cell cycle progression.

Roscovitine, a potent CDK inhibitor, and Nocodazole, a microtubule-depolymerizing agent, further exemplify fzr inhibition by disrupting the signaling pathways involving fzr. Purvalanol A, BI2536, and GW843682X showcase fzr inhibition through their respective targets: CDKs, polo-like kinase 1 (PLK1), and Aurora B kinase. Olomoucine and Flavopiridol, both CDK inhibitors, contribute to fzr inhibition by disrupting CDK-mediated fzr phosphorylation events. VX-680 (Tozasertib) and BI-6727 (Volasertib) target fzr indirectly by inhibiting Aurora kinases and PLK1, respectively. Lastly, AZD7762 inhibits fzr by targeting checkpoint kinases (CHK1 and CHK2), disrupting their role in regulating fzr phosphorylation events during the cell cycle. This comprehensive set of fzr inhibitors provides valuable tools for dissecting the intricate molecular mechanisms governing fzr activity.